Artelo Biosciences Inc (NASDAQ:ARTL) shares surged 114.2% following the presentation of encouraging preclinical data for its CBD and TMP cocrystal drug candidate, ART12.11, at the 35th Annual International Cannabinoid Research Society Symposium.
The clinical-stage pharma company reported that ART12.11 exhibited strong antidepressant-like effects in animal studies, with efficacy comparable to sertraline (Zoloft), a widely prescribed selective serotonin reuptake inhibitor. The data was presented by Matt Jones, a scientist from Professor Steven Laviolette’s lab at the University of Western Ontario.
During a 28-day treatment course, ART12.11 significantly reversed behavioral impairments in male rats subjected to chronic stress. The compound restored sucrose preference and social motivation—key markers of depressive-like behavior—to nearly normal levels.
Importantly, ART12.11 also demonstrated superior cognitive recovery compared to sertraline, reversing stress-induced deficits in spatial and short-term memory without adversely affecting social memory. This unique profile suggests potential as a treatment for depression and anxiety, especially in patients suffering from cognitive dysfunction.
“Our latest behavioral studies suggest that the cocrystal holds strong potential as a novel antidepressant,” said Matt Jones, the lead researcher at the University of Western Ontario. He highlighted that ART12.11 restored pleasure and social motivation on par with sertraline while also reversing cognitive impairments where sertraline was less effective.
Gregory D. Gorgas, President and CEO of Artelo Biosciences, expressed optimism about the findings, noting that ART12.11 could address a significant unmet need in mental health by providing both mood-enhancing and cognitive benefits.